- Home
- PPBT vs EDSA Comparison
PPBT vs EDSA Comparison
Compare PPBT & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- EDSA
- Stock Information
- Founded
- PPBT 2010
- EDSA 2015
- Country
- PPBT Israel
- EDSA Canada
- Employees
- PPBT N/A
- EDSA N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- PPBT Health Care
- EDSA Health Care
- Exchange
- PPBT Nasdaq
- EDSA Nasdaq
- Market Cap
- PPBT 9.2M
- EDSA 11.0M
- IPO Year
- PPBT N/A
- EDSA N/A
- Fundamental
- Price
- PPBT $2.51
- EDSA $2.09
- Analyst Decision
- PPBT Strong Buy
- EDSA Strong Buy
- Analyst Count
- PPBT 2
- EDSA 1
- Target Price
- PPBT $126.50
- EDSA $21.00
- AVG Volume (30 Days)
- PPBT 61.9K
- EDSA 50.3K
- Earning Date
- PPBT 11-15-2024
- EDSA 12-13-2024
- Dividend Yield
- PPBT N/A
- EDSA N/A
- EPS Growth
- PPBT N/A
- EDSA N/A
- EPS
- PPBT N/A
- EDSA N/A
- Revenue
- PPBT N/A
- EDSA N/A
- Revenue This Year
- PPBT N/A
- EDSA N/A
- Revenue Next Year
- PPBT N/A
- EDSA N/A
- P/E Ratio
- PPBT N/A
- EDSA N/A
- Revenue Growth
- PPBT N/A
- EDSA N/A
- 52 Week Low
- PPBT $2.43
- EDSA $2.09
- 52 Week High
- PPBT $23.20
- EDSA $6.46
- Technical
- Relative Strength Index (RSI)
- PPBT 28.04
- EDSA 19.32
- Support Level
- PPBT $2.50
- EDSA $2.26
- Resistance Level
- PPBT $2.82
- EDSA $2.44
- Average True Range (ATR)
- PPBT 0.38
- EDSA 0.26
- MACD
- PPBT 0.04
- EDSA -0.06
- Stochastic Oscillator
- PPBT 5.10
- EDSA 0.00
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.